Cargando…

Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients

Anti-CMV (cytomegalovirus) antibody titers are related to immune alterations and increased risk of mortality. To test whether they represent a marker of infection history, we analyzed the effect of viral reactivations on the production of specific antibodies in kidney transplant patients. We quantif...

Descripción completa

Detalles Bibliográficos
Autores principales: Iglesias-Escudero, María, Moro-García, Marco Antonio, Marcos-Fernández, Raquel, García-Torre, Alejandra, Álvarez-Argüelles, Marta Elena, Suárez-Fernández, María Luisa, Martínez-Camblor, Pablo, Rodríguez, Minerva, Alonso-Arias, Rebeca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895001/
https://www.ncbi.nlm.nih.gov/pubmed/29641536
http://dx.doi.org/10.1371/journal.pone.0194789
_version_ 1783313582358790144
author Iglesias-Escudero, María
Moro-García, Marco Antonio
Marcos-Fernández, Raquel
García-Torre, Alejandra
Álvarez-Argüelles, Marta Elena
Suárez-Fernández, María Luisa
Martínez-Camblor, Pablo
Rodríguez, Minerva
Alonso-Arias, Rebeca
author_facet Iglesias-Escudero, María
Moro-García, Marco Antonio
Marcos-Fernández, Raquel
García-Torre, Alejandra
Álvarez-Argüelles, Marta Elena
Suárez-Fernández, María Luisa
Martínez-Camblor, Pablo
Rodríguez, Minerva
Alonso-Arias, Rebeca
author_sort Iglesias-Escudero, María
collection PubMed
description Anti-CMV (cytomegalovirus) antibody titers are related to immune alterations and increased risk of mortality. To test whether they represent a marker of infection history, we analyzed the effect of viral reactivations on the production of specific antibodies in kidney transplant patients. We quantified CMV-DNAemia and antibody titers in 58 kidney transplant patients before transplantation and during a follow-up of 315 days (standard deviation, SD: 134.5 days). In order to calculate the intensity of the infection, we plotted the follow-up time of the infection on the x-axis and the number of DNA-CMV copies on the y-axis and calculated the area under the curve (CMV-AUC). The degree of T-lymphocyte differentiation was analyzed with flow cytometry, the cells were labelled with different monoclonal antibodies in order to distinguish their differentiation state, from naive T-cells to senescent T-cells. Peak viremia was significantly higher in patients experiencing a primary infection (VI) compared to patients experiencing viral reactivation (VR). Our data indicate that the overall CMV viral load over the course of a primary infection is significantly higher than in a reactivation of a previously established infection. Whereas patients who experienced an episode of CMV reactivation during the course of our observation showed increased levels of CMV-specific antibodies, patients who did not experience CMV reactivation (WVR) showed a drop in CMV antibody levels that corresponds to an overall drop in antibody levels, probably due to the continuing immunosuppression after the renal transplant. We found a positive correlation between the CMV viremia over the course of the infection or reactivation and the CMV-specific antibody titers in the examined patients. We also observed a positive correlation between anti-CMV titers and T-cell differentiation. In conclusion, our data show that anti-CMV antibody titers are related to the course of CMV infection in kidney transplant patients.
format Online
Article
Text
id pubmed-5895001
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58950012018-05-04 Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients Iglesias-Escudero, María Moro-García, Marco Antonio Marcos-Fernández, Raquel García-Torre, Alejandra Álvarez-Argüelles, Marta Elena Suárez-Fernández, María Luisa Martínez-Camblor, Pablo Rodríguez, Minerva Alonso-Arias, Rebeca PLoS One Research Article Anti-CMV (cytomegalovirus) antibody titers are related to immune alterations and increased risk of mortality. To test whether they represent a marker of infection history, we analyzed the effect of viral reactivations on the production of specific antibodies in kidney transplant patients. We quantified CMV-DNAemia and antibody titers in 58 kidney transplant patients before transplantation and during a follow-up of 315 days (standard deviation, SD: 134.5 days). In order to calculate the intensity of the infection, we plotted the follow-up time of the infection on the x-axis and the number of DNA-CMV copies on the y-axis and calculated the area under the curve (CMV-AUC). The degree of T-lymphocyte differentiation was analyzed with flow cytometry, the cells were labelled with different monoclonal antibodies in order to distinguish their differentiation state, from naive T-cells to senescent T-cells. Peak viremia was significantly higher in patients experiencing a primary infection (VI) compared to patients experiencing viral reactivation (VR). Our data indicate that the overall CMV viral load over the course of a primary infection is significantly higher than in a reactivation of a previously established infection. Whereas patients who experienced an episode of CMV reactivation during the course of our observation showed increased levels of CMV-specific antibodies, patients who did not experience CMV reactivation (WVR) showed a drop in CMV antibody levels that corresponds to an overall drop in antibody levels, probably due to the continuing immunosuppression after the renal transplant. We found a positive correlation between the CMV viremia over the course of the infection or reactivation and the CMV-specific antibody titers in the examined patients. We also observed a positive correlation between anti-CMV titers and T-cell differentiation. In conclusion, our data show that anti-CMV antibody titers are related to the course of CMV infection in kidney transplant patients. Public Library of Science 2018-04-11 /pmc/articles/PMC5895001/ /pubmed/29641536 http://dx.doi.org/10.1371/journal.pone.0194789 Text en © 2018 Iglesias-Escudero et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Iglesias-Escudero, María
Moro-García, Marco Antonio
Marcos-Fernández, Raquel
García-Torre, Alejandra
Álvarez-Argüelles, Marta Elena
Suárez-Fernández, María Luisa
Martínez-Camblor, Pablo
Rodríguez, Minerva
Alonso-Arias, Rebeca
Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients
title Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients
title_full Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients
title_fullStr Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients
title_full_unstemmed Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients
title_short Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients
title_sort levels of anti-cmv antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895001/
https://www.ncbi.nlm.nih.gov/pubmed/29641536
http://dx.doi.org/10.1371/journal.pone.0194789
work_keys_str_mv AT iglesiasescuderomaria levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT morogarciamarcoantonio levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT marcosfernandezraquel levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT garciatorrealejandra levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT alvarezarguellesmartaelena levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT suarezfernandezmarialuisa levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT martinezcamblorpablo levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT rodriguezminerva levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients
AT alonsoariasrebeca levelsofanticmvantibodiesaremodulatedbythefrequencyandintensityofvirusreactivationsinkidneytransplantpatients